What is HC Wainwright’s Forecast for TCRX FY2026 Earnings?

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities researchers at HC Wainwright lowered their FY2026 earnings estimates for shares of TScan Therapeutics in a report issued on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($0.91) for the year, down from their previous estimate of ($0.88). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for TScan Therapeutics’ FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.91) EPS, FY2029 earnings at ($0.80) EPS and FY2030 earnings at ($0.16) EPS.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 97.00%. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.88 million.

TCRX has been the topic of a number of other research reports. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of TScan Therapeutics in a report on Tuesday, June 23rd. Wedbush reiterated an “outperform” rating and set a $5.00 price target on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Benchmark reissued a “buy” rating on shares of TScan Therapeutics in a report on Thursday. Wall Street Zen downgraded shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $6.00.

TScan Therapeutics Stock Down 0.1%

TScan Therapeutics stock opened at $0.77 on Friday. The firm has a market capitalization of $50.45 million, a price-to-earnings ratio of -0.85 and a beta of 1.06. The firm’s fifty day moving average price is $0.90 and its two-hundred day moving average price is $1.01. TScan Therapeutics has a 1-year low of $0.72 and a 1-year high of $2.57. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.34.

Institutional Trading of TScan Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in TScan Therapeutics in the second quarter worth about $975,000. GSA Capital Partners LLP bought a new stake in shares of TScan Therapeutics in the 2nd quarter worth approximately $537,000. Renaissance Technologies LLC lifted its stake in TScan Therapeutics by 37.5% in the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock valued at $1,141,000 after purchasing an additional 311,150 shares during the last quarter. Jane Street Group LLC lifted its stake in TScan Therapeutics by 377.5% in the fourth quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock valued at $388,000 after purchasing an additional 306,968 shares during the last quarter. Finally, Marshall Wace LLP grew its holdings in TScan Therapeutics by 627.5% during the fourth quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock valued at $339,000 after purchasing an additional 292,610 shares during the period. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.